These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Characteristics of D-1 dopamine receptors labelled by [3H]fluphenazine in homogenates of rat neostriatum. Cincotta M; de Vries DJ; Beart PM Neurosci Lett; 1985 Oct; 61(1-2):85-9. PubMed ID: 2867505 [TBL] [Abstract][Full Text] [Related]
24. Cerebral metabolism in experimental hydrocephalus: an in vivo 1H and 31P magnetic resonance spectroscopy study. Braun KP; van Eijsden P; Vandertop WP; de Graaf RA; Gooskens RH; Tulleken KA; Nicolay K J Neurosurg; 1999 Oct; 91(4):660-8. PubMed ID: 10507389 [TBL] [Abstract][Full Text] [Related]
25. Clinical perspectives of hybrid proton-fluorine magnetic resonance imaging and spectroscopy. Wolters M; Mohades SG; Hackeng TM; Post MJ; Kooi ME; Backes WH Invest Radiol; 2013 May; 48(5):341-50. PubMed ID: 23211551 [TBL] [Abstract][Full Text] [Related]
26. Comparison of the in vivo and in vitro nuclear magnetic resonance detection of trifluoromethyl penicillin V in rats. Campbell GD; Ramaprasad S; Olsen KM; Tryka AF; Komoroski RA; Blaszczak LC; Parr TR J Pharm Sci; 1993 Jan; 82(1):48-51. PubMed ID: 8429491 [TBL] [Abstract][Full Text] [Related]
27. Effects of neuroleptic drugs on brain beta-endorphin immunoreactivity. Beal MF; Fisher J; Carr DB; Martin JB Neurosci Lett; 1985 Jan; 53(2):173-8. PubMed ID: 2858834 [TBL] [Abstract][Full Text] [Related]
28. Development of an in vivo 19F magnetic resonance method for measuring oxygen deficiency in tumors. Raleigh JA; Franko AJ; Kelly DA; Trimble LA; Allen PS Magn Reson Med; 1991 Dec; 22(2):451-66. PubMed ID: 1812379 [TBL] [Abstract][Full Text] [Related]
30. Preparation of fluorinated antibiotics followed by 19F NMR spectroscopy. I. Fluorinated vulgamycins. Kawashima A; Seto H; Kato M; Uchida K; Otake N J Antibiot (Tokyo); 1985 Nov; 38(11):1499-505. PubMed ID: 4077730 [TBL] [Abstract][Full Text] [Related]
31. Chronic treatment with a classical neuroleptic alters excitatory amino acid and GABAergic neurotransmission in specific regions of the rat brain. Johnson AE; Liminga U; Lidén A; Lindefors N; Gunne LM; Wiesel FA Neuroscience; 1994 Dec; 63(4):1003-20. PubMed ID: 7535390 [TBL] [Abstract][Full Text] [Related]
32. Preclinical studies with compound GYKI-22441, a new long-acting neuroleptic phenothiazine. Király I; Borsy J; Tapfer M; Losonczy S; Rásky K; Toldy L; Tóth I Acta Physiol Hung; 1990; 75 Suppl():171-2. PubMed ID: 1973563 [No Abstract] [Full Text] [Related]
33. Noninvasive in vivo demonstration of 2-fluoro-2-deoxy-D-glucose metabolism beyond the hexokinase reaction in rat brain by 19F nuclear magnetic resonance spectroscopy. Nakada T; Kwee IL; Conboy CB J Neurochem; 1986 Jan; 46(1):198-201. PubMed ID: 3940280 [TBL] [Abstract][Full Text] [Related]
34. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels. Jayaram G; Coyle J; Tune L J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342 [TBL] [Abstract][Full Text] [Related]
35. In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. el-Tahtawy A; Wolf W Cancer Res; 1991 Nov; 51(21):5806-12. PubMed ID: 1933851 [TBL] [Abstract][Full Text] [Related]
36. Animal model for investigation of fluphenazine kinetics after administration of long-acting esters. Altamura AC; Whelpton R; Curry SH Biopharm Drug Dispos; 1979; 1(2):65-72. PubMed ID: 552863 [TBL] [Abstract][Full Text] [Related]
37. (+/-)-7-chloro-8-hydroxy-1-(4'-[125I]iodophenyl)-3-methyl-2,3,4,5- tetrahydro-1H-3-benzazepine: a potential CNS D-1 dopamine receptor imaging agent. Chumpradit S; Kung HF; Billings J; Kung MP; Pan S J Med Chem; 1989 Jul; 32(7):1431-5. PubMed ID: 2525621 [TBL] [Abstract][Full Text] [Related]
38. Novel non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Studies in the SCCVII/C3H murine model. Papadopoulou MV; Pouremad R; Bloomer WD; Wyrwicz A Anticancer Res; 2006; 26(5A):3259-63. PubMed ID: 17094438 [TBL] [Abstract][Full Text] [Related]
39. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation. Soni SD; Sampath G; Shah A; Krska J Acta Psychiatr Scand; 1992 May; 85(5):354-9. PubMed ID: 1351333 [TBL] [Abstract][Full Text] [Related]